Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 9 Sarcoma 5 Recurrence 5 Neoplasm Metastasis 5 Lymphoma 5 Breast Neoplasms 5 Endometrial Neoplasms 4 Ovarian Neoplasms 3 Solid Tumors 2 Prostatic Neoplasms 2 Multiple Myeloma 2 Glioblastoma 2 Carcinoma, Non-Small-Cell Lung 2 Solid Tumor 1 Primary Myelofibrosis 1 Osteosarcoma 1 Myelodysplastic Syndromes 1 Liposarcoma 1 Leukemia 1 Leiomyosarcoma 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Bone Neoplasms 1 Advanced Cancers 1

Interventions

Ibandronic Acid 8 Gemcitabine 8 Doxorubicin 6 Cyclophosphamide 6 Zoledronic Acid 5 Radiation 4 Nivolumab 4 Irinotecan 4 pembrolizumab 3 Vincristine 3 Temozolomide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Docetaxel 3 Cisplatin 3 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 3 regorafenib 2 pegfilgrastim 2 Tranexamic Acid 2 Trabectedin 2 Sunitinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiosurgery 2 Proton Therapy 2 Methotrexate 2 Injections 2 Ifosfamide 2 Etoposide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Bone Neoplasms × ridaforolimus × Clear all

NCT00538239 2015-02-13

SUCCEED

Merck Sharp & Dohme LLC

Phase 3 Completed

Bone Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡